Trial Profile

An observational study of NIDO-361 in patients with SBMA

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NIDO-361 (Primary)
Indications Spinal muscular atrophy
Focus Therapeutic Use

Most Recent Events

06 Nov 2023 New trial record
05 Nov 2023 According to Nido Biosciences media release, The two year observational study being conducted at the National Institute of Neurological Disorders and Stroke (NINDS)/National Institute of Health (NIH), the University College London (UCL), and the Department of Neurology, Nagoya University Graduate School of Medicine (Nagoya)
05 Nov 2023 Interim Results presented in the Nido Biosciences Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com